KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Cash & Current Investments (2016 - 2026)

Amgen has reported Cash & Current Investments over the past 18 years, most recently at $12.0 billion for Q1 2026.

  • For Q1 2026, Cash & Current Investments rose 36.64% year-over-year to $12.0 billion; the TTM value through Mar 2026 reached $12.0 billion, up 36.64%, while the annual FY2025 figure was $9.1 billion, 23.75% down from the prior year.
  • Cash & Current Investments for Q1 2026 was $12.0 billion at Amgen, up from $9.1 billion in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $34.7 billion in Q3 2023 and troughed at $6.5 billion in Q1 2022.
  • A 5-year average of $13.7 billion and a median of $9.4 billion in 2025 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 382.29% in 2023 and later crashed 74.06% in 2024.
  • Year by year, Cash & Current Investments stood at $9.3 billion in 2022, then rose by 17.61% to $10.9 billion in 2023, then increased by 9.4% to $12.0 billion in 2024, then fell by 23.75% to $9.1 billion in 2025, then surged by 31.87% to $12.0 billion in 2026.
  • Business Quant data shows Cash & Current Investments for AMGN at $12.0 billion in Q1 2026, $9.1 billion in Q4 2025, and $9.4 billion in Q3 2025.